About this episode

Dr. Segev reviews key TXA trials and highlights updated guidelines for its use in trauma care.

Tranexamic acid (TXA) is an anti-fibrinolytic that may reduce hemorrhage and improve survival in trauma. While early studies raised safety concerns, newer evidence supports its use in select patients. Join Dr. Segev as he reviews key TXA trials and highlights the updated EAST guidelines on pre-hospital and in-hospital administration.

People in this episode

Guest: Dr. Segev

Topics covered

• TXA
• trauma
• hemorrhage
• survival
• EAST guidelines
• pre-hospital care
• in-hospital administration

Keywords

• TXA
• tranexamic acid
• trauma
• hemorrhage
• EAST guidelines
• pre-hospital administration
• in-hospital administration

Mentioned in this episode

Organizations: EAST

Products: Tranexamic acid (TXA)

More episodes of TamingtheSRU

• Two‑Bag Triumph? What the Evidence Really Shows in Diabetic Ketoacidosis Care · May 22, 2026 · 4 min
• Ambient AI Scribe in the ED: Game-Changer or Just Hype? · April 14, 2026 · 6 min
• When Seconds Count: Can Drone-AED Networks Change OHCA Survival? · March 26, 2026 · 5 min
• Trip, Slip, Scan? Rethinking Head CTs in the Elderly · December 15, 2025 · 8 min
• When More is Less: Re-examining CTA use in GI Bleeds · November 6, 2025 · 5 min
• COPY That: Re-thinking Pyelonephritis Protocols in the Emergency Department · October 3, 2025 · 6 min

Explore listener stats, chart rankings, contacts and more on the TamingtheSRU podcast page.